Taha et al. described the clinical courses of two lymphoma patients: a patient with FL treated with multiple therapies, including CD20/anti-CD3 bispecific antibody, and a patient with anti-PD-L1 and CLL under ibrutinib treatment [14]. The gene discussed is CD274; the disease is lymphoma.